Why Thermo Fisher Scientific’s ASMS 2026 launch matters for drug discovery workflows
Thermo Fisher Scientific unveils new Orbitrap platforms at ASMS 2026. Find out how they could reshape drug discovery workflows today!
Why Aphios’ Bryoid composition patent matters beyond Alzheimer’s disease research
Aphios has a new Bryoid patent allowance. The bigger test is whether marine-derived PKC biology can move from IP promise to clinical proof.
Drug discovery has an AI problem. Clicklinks thinks the answer is connection, not just algorithms
Find out how Sanyou Bio’s Clicklinks platform could reshape AI-led drug discovery by linking biotech, CRO, CDMO and preclinical resources.
Can Anthropic’s Claude help Bristol Myers Squibb speed up medicine discovery and delivery?
Bristol Myers Squibb is moving AI from pilots to enterprise scale. Claude’s real test is governance, data trust and drug development impact.
Concept Life Sciences expands drug discovery model as OpenBench brings AI-enabled screening scale
Biotechs need faster hits with less upfront risk. Concept Life Sciences and OpenBench are testing whether success-based discovery can deliver.
Why Bristol Myers Squibb’s $15.2bn Hengrui alliance signals a pipeline reset
Big Pharma needs faster pipelines. Bristol Myers Squibb’s Hengrui pact shows why China’s R&D engine is becoming harder to ignore.
ACROBiosystems makes HEK293 functional cell lines easier to use in global R&D workflows
HEK293 tools are everywhere, but licensing slows teams down. ACROBiosystems is turning compliance clarity into an R&D advantage.
Are autonomous labs quietly turning biopharma researchers into scientific strategists?
Autonomous labs can run experiments faster. The bigger shift is what happens when biopharma researchers stop executing and start directing.
WuXi Biologics to support Vertex’s autoimmune TCE R&D with full CRDMO integration
Vertex licenses trispecific TCE from WuXi Biologics for autoimmune drug R&D. Explore platform risks, modality fit, and strategic expansion in this analysis.
FAR Biotech expands to Madison: What this means for AI-based drug development
FAR Biotech brings its QuantumAI platform to Madison. Find out what this move means for drug discovery, platform scalability, and Wisconsin’s biohealth future.